Comparing bioequivalence of oral cholecalciferol and ergocalciferol treatment for 3 months in Australian hip fracture cases

Phase 4

Active, not recruiting

• Conditions: Vitamin D deficiency; Hip fractures; Musculoskeletal - Osteoporosis

• Registration Number: ACTRN12608000381381
• Lead Sponsor: Medical Research Foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-08-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Hip fracture
Residing in Perth metropolitan area

Exclusion Criteria

Ionised hypercalcemia
History of thyrotoxicosis/Cushings in last 2 years
Anticonvulsant medication use
Current or within last 3 months use of estrogen, raloxifene, calcitriol, anabolic steroids, bisphosphonates, sodium fluoride or corticosteroids
Renal failre as defined by serum creatinine > 150 umol/L
Patients unlikely to comply or live longer than 3 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Increase in 25 hydroxyvitamin D as measured by high performance liquid chromatography[Single measurement at baseline and on completion of 3 months study]

Secondary Outcome Measures

Name	Time	Method
Increase in 1,25 dihydroxyvitamin D as measured by radioimmunoassay[Single measurement at baseline and on completion of 3 months study];Increase in 25-hydroxyvitamin D as measured by radioimmunoassay[Single measurement at baseline and on completion of 3 months study];Change in parathyroid hormone[Single measurement at baseline and on completion of 3 months study];Change in vitamin D binding protein[Single measurement at baseline and on completion of 3 months study];Increase in 25 OHD as measured by diasorin Radioimunoassay[Single measurement at baseline and on completion of 3 months study]